Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease

By A. Dunah, Hyunkyung Jeong, A. Griffin, Yong-Man Kim, D. Standaert, S. Hersch, M. Mouradian, A. Young, N. Tanese, D. Krainc. Science, 2002

715 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “TFIID, TFIIF, and TAFII130, which are components of the core transcriptional machinery, are direct targets of mutant huntingtin (162, 523, 659).”
Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice (2003, neutral): “Nonspecific binding was inhibited by incubation in Tris-buffered saline–Tween 20 (TBST) (50 mM Tris HCl, pH 8.0, 0.9% NaCl, 0.1% Tween 20) containing 5% nonfat dry milk for 0.5 hr. Primary antibodies against Sp1 (PEP2; Santa Cruz Biotechnology, Santa Cruz, CA) were diluted at 1:1000 in 1% milk TBST ”
Hydrogen peroxide sensing, signaling and regulation of transcription factors (2014, background): “SP1 directly interacts with TATA-binding protein associated factors [123] and other factors, such as those binding to cAMP response elements [124], NF-B [125] and vascular endothelial growth factor receptor-2 (VEGFR-2) [126].”